A variant neoplastic line of human pluripotent stem cell (hPSC) displays unique tumorigenic properties, including enhanced self-renewal and survival, and aberrant blockade in differentiation. Sachlos et al. adopted a neoplastic hPSC differentiation platform to screen small molecules that selectively induce differentiation of cancer stem cells.
Recent studies support a hypothesis in which subpopulations of tumor cells, tumor initiating cells (TICs), drive tumorigenesis and give rise to a large population of differentiated progenies that make up most of a tumor. Although conventional chemotherapies reduce the bulk of the tumor by effectively eliminating highly proliferative cancer cells, refractory TICs allow tumors to recur and thus account for many treatment failures. The drug resistance of TICs may be due to their restricted cell cycle and quiescence; higher expression of drug pumps; and/or enhanced antioxidative, antiapoptotic, DNA repair, and self-renewal mechanisms, many of which are also shared by tissue-specific normal stem cells. Consequently, differentially targeting TICs, while sparing normal stem cells, is a major challenge. However, one strategy might address that challenge. TICs with oncogenic molecular alterations may be more addicted to those above enhanced stem cell mechanisms and therefore targeting such deregulation may sensitize TICs to treatments (Frank et al., 2010) . For example, shifting enhanced self-renewal to the normal level may effectively render TICs more susceptible to conventional therapy.
Several studies used chemical genetics approaches to model the differentiation of stem cells and TICs. Chemical libraries were screened in hESCs (Desbordes et al., 2008) or cancer cells with certain stem-like properties (Gupta et al., 2009) to identify compounds that maintain or inhibit their self-renewal, providing tools to interrogate underlying mechanisms. However, drug discovery for differentially targeting TICs (Shen et al., 2004) has been hindered by difficulties in homogenously expanding and maintaining rare TICs in vitro ( Figure 1A ). This problem was addressed by developing specific conditions for stably expanding certain subpopulation of TICs (Pollard et al., 2009 ).
In an interesting report published in this issue of Cell, Sachlos et al. (2012) provide another attractive approach. They interrogated neoplastic human pluripotent stem cell (hPSC) as a human TIC surrogate for high-content screening of differentiation inducing agents ( Figure 1B ). Compounds identified with this model were further shown to selectively decrease the number of human CD33+ hCD45+ acute myeloid leukemia (AML) cells in a xenotransplantation model. This demonstrates the feasibility of finding therapeutic candidates for differentially targeting TIC differentiation and therapeutic potentials of such strategy for treating cancer.
Neoplastic hPSC is a culture-adapted variant hESC line (Werbowetski-Ogilvie et al., 2009 ) with subkaryotypic abnormalities that exhibits acquired tumorigenic features, including enhanced self-renewal with reduced growth factor dependence and blocked differentiation. Its FGFR1 and IGFR1 coexpression pattern is similar to that of teratocarcinoma, and its derived neural progenitors are tumorigenic in recipient mice. These features support its resemblance to TICs at the top of tumor hierarchy, providing a basis as a surrogate model to interrogate TIC differentiation. Reporter lines of the neoplastic hPSCs with transgenic Oct4-GFP (as a pluripotency marker) were generated and used in screening a known drug library, where GFP intensity reflected differentiation status. The confirmed hits that significantly reduced GFP expression were subsequently tested in normal hESCs to further select compounds only selectively and nontoxically inducing neoplastic hPSC differentiation.
Among 26 hits identified from 2,446 compounds, thioridazine, a selective dopamine receptor (DR) antagonist used to treat the symptoms of schizophrenia, was further characterized. In functional studies involving xenotransplantation of leukemia stem cells from AML patient samples, thioridazine treatment impaired the leukemogenesis function of those AML stem cells, while sparing the normal hematopoietic stem/progenitor cells (HSPCs). In contrast, salinomycin, an antibiotic that targets breast cancer stem cells, significantly reduced hematopoietic engraftment, indicating that the normal HSPCs were impaired. Because many TICs are quiescent and their initiated differentiation may drive more active cell cycling, a combination of thioridazine and the antiproliferative AraC was further demonstrated as a more effective treatment in the AML model, supporting the therapeutic potential of inducing TIC differentiation. Interestingly, the study suggested that thioridazine may exert its effect by antagonizing D2-family DRs. This is consistent with the observation that male patients receiving DR antagonism treatment had a lower incidence of rectum cancer and prostate cancer. However, the mechanism by which DR signaling regulates TIC self-renewal will require further elucidation.
Although the use of neoplastic hPSC as a TIC surrogate provides a useful approach for identifying compounds with selective differentiation inducing activity on TICs, many challenges remain in anticancer drug discovery. In various types of tumors developed from distinct cells of origin and microenvironments (niches) through serial oncogenic, genetic, and epigenetic changes, the deregulated self-renewal ability of TICs strongly depend on the context, and TICs (if they exist) from different types of tumors at different stages may rely on different deregulated self-renewal mechanisms. In addition, some tumor types do not exclusively follow a TIC model (Shackleton et al., 2009) . Extrinsically, TICs are regulated by a tumor-conferring niche created by heterogeneous populations of tumor and nontumor cells (Hanahan and Weinberg, 2011) . Thus, the selfrenewal mechanism involved in a nichedependent in vivo context of a primary tumor might be fundamentally different from the mechanism in a niche-independent in vitro context. Therefore, future challenges lie in establishing an anticancer drug screening model that recapitulates specific molecular alterations under intrinsically and extrinsically specific contexts.
Despite these challenges, Sachlos and colleagues' work, together with recent studies involving reprogramming nontumorigenic cancer cells to stem-like cancer cells (Guo et al., 2012) , provides an innovative strategy for modeling TICs ( Figure 1C ). These advances may also lead to the possibility of generating a neoplastic hPSC line for each tumor type by the induced pluripotent stem cell technology ( Figure 1D ). Thus, conceivably, the development of reprogrammed, genetically distinct neoplastic hiPSC models with an appropriate in vitro niche interaction mechanism would provide a context-specific drug discovery platform for new cancer therapeutic development. 
